JP2008530100A - 視覚障害の治療方法 - Google Patents

視覚障害の治療方法 Download PDF

Info

Publication number
JP2008530100A
JP2008530100A JP2007555184A JP2007555184A JP2008530100A JP 2008530100 A JP2008530100 A JP 2008530100A JP 2007555184 A JP2007555184 A JP 2007555184A JP 2007555184 A JP2007555184 A JP 2007555184A JP 2008530100 A JP2008530100 A JP 2008530100A
Authority
JP
Japan
Prior art keywords
compound
acid
administering
visual impairment
retinal degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007555184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530100A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ． スティア，クリフフォード
シー． ロウ，ワルター
ダブリュ． オルセン，ティモシー
エイチ． ボートライト，ジェフリー
エム． ニッカーソン，ジョン
エミ．ペー． ロドリゲス，セシリア
ティー． パーデュ，マシエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
University of Minnesota Twin Cities
Original Assignee
Emory University
University of Minnesota Twin Cities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, University of Minnesota Twin Cities filed Critical Emory University
Publication of JP2008530100A publication Critical patent/JP2008530100A/ja
Publication of JP2008530100A5 publication Critical patent/JP2008530100A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2007555184A 2005-02-10 2006-02-08 視覚障害の治療方法 Withdrawn JP2008530100A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65172905P 2005-02-10 2005-02-10
PCT/US2006/004394 WO2006086452A1 (en) 2005-02-10 2006-02-08 Methods for treating visual disorders

Publications (2)

Publication Number Publication Date
JP2008530100A true JP2008530100A (ja) 2008-08-07
JP2008530100A5 JP2008530100A5 (cg-RX-API-DMAC7.html) 2009-04-23

Family

ID=36602737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555184A Withdrawn JP2008530100A (ja) 2005-02-10 2006-02-08 視覚障害の治療方法

Country Status (5)

Country Link
US (1) US20080194531A1 (cg-RX-API-DMAC7.html)
EP (1) EP1871385A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008530100A (cg-RX-API-DMAC7.html)
KR (1) KR20080012258A (cg-RX-API-DMAC7.html)
WO (1) WO2006086452A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143192A (ja) * 2017-02-09 2021-09-24 アミコゲン ファーマ インコーポレイテッド ウルソデオキシコール酸を含有する視覚障害の予防または治療用組成物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724357B2 (en) * 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
CN105358147A (zh) * 2013-07-01 2016-02-24 贝斯迪大药厂 牛磺熊去氧胆酸（tudca）用于治疗神经退行性疾病的用途
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
EP3064222B1 (en) * 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
CN104083381A (zh) * 2014-07-29 2014-10-08 上海中医药大学 熊去氧胆酸的医药用途
KR20180029317A (ko) * 2016-09-12 2018-03-21 경상대학교산학협력단 간손상 예방, 개선 또는 치료용 조성물
KR20180036580A (ko) 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
WO2018147685A1 (ko) * 2017-02-09 2018-08-16 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2020072468A1 (en) 2018-10-01 2020-04-09 Biovisics Medical, Llc System and methods for controlled electrical modulation for vision therapy
US11305118B2 (en) 2018-11-30 2022-04-19 Biovisics Medical, Inc. Head worn apparatuses for vision therapy
WO2020210471A1 (en) 2019-04-10 2020-10-15 Biovisics Medical, Inc. Systems and interfaces for ocular therapy
WO2020252278A1 (en) 2019-06-14 2020-12-17 Biovisics Medical, Inc. Wearable medical device
WO2021011255A1 (en) 2019-07-12 2021-01-21 Biovisics Medical, Inc. Ocular therapy modes and systems
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090876A1 (en) * 1991-07-03 1993-01-04 Satoru Nakai Apoptosis regulating composition
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
WO1999015179A1 (en) * 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
CA2321565C (en) * 1998-02-27 2014-10-14 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
CA2445091A1 (en) * 2000-12-13 2002-06-20 Janos Feher Pharmaceutical compositions for treatment of digestive disorders and associated diseases
CA2458068A1 (en) * 2001-08-20 2003-02-27 Tatton Technologies, Llc. Methods and compositions for treating apoptosis associated disorders
WO2004043342A2 (en) * 2002-11-07 2004-05-27 Regents Of The University Of Minnesota Methods of treating injuries of the nervous system associated with hemorrhage
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021143192A (ja) * 2017-02-09 2021-09-24 アミコゲン ファーマ インコーポレイテッド ウルソデオキシコール酸を含有する視覚障害の予防または治療用組成物

Also Published As

Publication number Publication date
KR20080012258A (ko) 2008-02-11
WO2006086452A1 (en) 2006-08-17
EP1871385A1 (en) 2008-01-02
US20080194531A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
JP2008530100A (ja) 視覚障害の治療方法
JP2008530100A5 (cg-RX-API-DMAC7.html)
US20250144080A1 (en) Compositions and methods for the treatment of macular degeneration
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
JP7335795B2 (ja) 薬学的組成物、および１，２，４－オキサジアゾール安息香酸の塩
KR102382077B1 (ko) 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
JP5959507B2 (ja) 神経保護性および網膜保護性医薬であるｎ−アセチル−ｄｌ−ロイシン
AU2006304553A1 (en) Method for treating primary and secondary forms of glaucoma
JP2002520287A (ja) 黄斑変性における血管新生の予防的治療
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
TWI815423B (zh) 用於治療近視的方法和藥物組合物
Samant et al. Pediatric glaucoma: pharmacotherapeutic options
Drenser et al. Crystalline retinopathies
CN102526006B (zh) 单羧酸和二羧酸的酰胺化物在肾病治疗中的应用
TWI816660B (zh) 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途
CN106659698A (zh) 基于藏红花的用于预防和/或治疗角膜营养不良的组合物
EP4087533B1 (en) Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
TW202011949A (zh) 苯甲酸或其鹽及衍生物用於預防或治療抗ｎ－甲基－ｄ－天冬胺酸受體腦炎之用途
TW202523286A (zh) 立汎黴素（ｒｉｆａｍｙｃｉｎ）的眼用組成物及其用途
US9114120B2 (en) Therapeutical method for the treatment of the Leber optic neuropathy
Bos Current treatment of atopic dermatitis
HK1135020A (en) Gel useful for the delivery of ophthalmic drugs
WO2007013591A1 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090303

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110225